Enhanced immune complex formation in the lungs of patients with dermatomyositis

Respiratory Research

Table 3 Subset analysis of immunohistochemical staining performed for clinical course

Expression intensity 0/1/2/3 (Mean ± SD)	Acute course^a			Chronic course^b
Expression intensity 0/1/2/3 (Mean ± SD)	DM-ILD (n = 9)	IPF (n = 9)	P value	DM-ILD (n = 9)	IPF (n = 10)	P value
C3c	0/3/4/2 (1.889 ± 0.782)	8/1/0/0 (0.111 ± 0.333)	< 0.001	3/4/2/0 (0.889 ± 0.782)	9/1/0/0 (0.100 ± 0.316)	0.007
IgG	0/2/5/2 (2.000 ± 0.707)	3/4/2/0 (0.889 ± 0.782)	0.011	0/2/7/0 (1.778 ± 0.441)	1/6/3/0 (1.200 ± 0.632)	0.037
IgM	5/3/1/0 (0.556 ± 0.726)	7/2/0/0 (0.222 ± 0.441)	0.286	2/7/0/0 (0.778 ± 0.441)	10/0/0/0 (0.000 ± 0.000)	0.001
IgA	1/6/0/2 (1.333 ± 1.000)	3/2/4/0 (1.111 ± 0.928)	0.779	4/5/0/0 (0.556 ± 0.527)	1/7/2/0 (1.100 ± 0.568)	0.051
MDA5	0/0/8/1 (2.111 ± 0.333)	0/0/7/2 (2.222 ± 0.441)	0.539	0/1/7/1 (2.000 ± 0.500)	0/0/7/3 (2.300 ± 0.483)	0.203

Expression intensity score 0, negative staining; score 1, weakly positive; score 2, moderately positive; and score 3, strongly positive. Details are described in the “Methods” section
DM dermatomyositis; ILD interstitial lung disease; IPF idiopathic pulmonary fibrosis; MDA5 melanoma differentiation-associated gene 5
^aAcute course: rapidly progressive ILD (RP-ILD) in patients with DM-ILD (n = 9) vs. Acute exacerbation (AE) in patients with IPF (n = 9)
^bChronic course: non-RP-ILD in patients with DM-ILD (n = 9) vs. Non-AE in patients with IPF (n = 10)

ISSN: 1465-993X